These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17148063)

  • 1. Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation.
    Forslöw U; Mattsson J; Ringden O; Klominek J; Remberger M
    Scand J Infect Dis; 2006; 38(11-12):970-6. PubMed ID: 17148063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation.
    Forslöw U; Blennow O; LeBlanc K; Ringdén O; Gustafsson B; Mattsson J; Remberger M
    Eur J Haematol; 2012 Sep; 89(3):220-7. PubMed ID: 22765507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
    Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
    Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors.
    Remberger M; Mattsson J; Hentschke P; Aschan J; Barkholt L; Svennilson J; Ljungman P; Ringdén O
    Bone Marrow Transplant; 2002 Dec; 30(11):761-8. PubMed ID: 12439699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular findings after allogeneic hematopoietic stem cell transplantation.
    Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
    Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation.
    Faulhaber GA; Furlanetto TW; Astigarraga CC; Moser Filho HL; Paludo AP; Silla LM
    Acta Haematol; 2010; 124(2):125-8. PubMed ID: 20861613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
    Du J; Liu J; Gu J; Zhu P
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
    Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.